1. Home
  2. INVE vs AGEN Comparison

INVE vs AGEN Comparison

Compare INVE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INVE
  • AGEN
  • Stock Information
  • Founded
  • INVE 1990
  • AGEN 1994
  • Country
  • INVE United States
  • AGEN United States
  • Employees
  • INVE N/A
  • AGEN N/A
  • Industry
  • INVE Computer peripheral equipment
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • INVE Technology
  • AGEN Health Care
  • Exchange
  • INVE Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • INVE 84.8M
  • AGEN 96.2M
  • IPO Year
  • INVE 1997
  • AGEN 2000
  • Fundamental
  • Price
  • INVE $3.62
  • AGEN $2.84
  • Analyst Decision
  • INVE Strong Buy
  • AGEN Buy
  • Analyst Count
  • INVE 2
  • AGEN 3
  • Target Price
  • INVE $7.25
  • AGEN $9.33
  • AVG Volume (30 Days)
  • INVE 76.1K
  • AGEN 478.9K
  • Earning Date
  • INVE 11-07-2024
  • AGEN 11-12-2024
  • Dividend Yield
  • INVE N/A
  • AGEN N/A
  • EPS Growth
  • INVE N/A
  • AGEN N/A
  • EPS
  • INVE 3.10
  • AGEN N/A
  • Revenue
  • INVE $104,217,000.00
  • AGEN $160,427,000.00
  • Revenue This Year
  • INVE N/A
  • AGEN N/A
  • Revenue Next Year
  • INVE N/A
  • AGEN $0.04
  • P/E Ratio
  • INVE $1.18
  • AGEN N/A
  • Revenue Growth
  • INVE 28.33
  • AGEN 59.00
  • 52 Week Low
  • INVE $2.95
  • AGEN $2.74
  • 52 Week High
  • INVE $9.24
  • AGEN $19.69
  • Technical
  • Relative Strength Index (RSI)
  • INVE 53.12
  • AGEN 20.16
  • Support Level
  • INVE $3.49
  • AGEN $2.98
  • Resistance Level
  • INVE $3.82
  • AGEN $4.42
  • Average True Range (ATR)
  • INVE 0.20
  • AGEN 0.26
  • MACD
  • INVE 0.01
  • AGEN -0.10
  • Stochastic Oscillator
  • INVE 43.55
  • AGEN 1.87

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: